Filing Flows › Relay Therapeutics (RLAY) › Q1 2026 › vs Q4 2025
Relay Therapeutics (RLAY) Q1 2026 vs Q4 2025 (quarter over quarter)
Relay Therapeutics's revenue fell $4.0M (-57%) from $7.0M in Q4 2025 to $3.0M in Q1 2026.
Relay Therapeutics, Q1 2026: revenue $3.0M (-61% year over year), net loss $73.3M, operating cash flow −$51.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $7.0M | −$4.0M | -57% |
| Other income, net | $5.3M | $5.7M | −$441K | -8% |
| Net loss | $73.3M | $54.9M | $18.4M | +34% |
| Costs & expenses | $81.6M | $67.6M | $14.0M | +21% |
| Operating costs | $81.6M | $67.6M | $14.0M | +21% |
| Research & development | $70.6M | $55.4M | $15.1M | +27% |
| General & admin | $11.0M | $12.2M | −$1.2M | -10% |
| Operating cash sources | $73.3M | $54.9M | $18.4M | +34% |
| Depreciation | $504K | $599K | −$95K | -16% |
| Share-based compensation | $10.5M | $13.1M | −$2.5M | -19% |
| Working capital & other | $11.1M | −$3.6M | $14.8M | — |
| Cash used in operations | $51.1M | $44.9M | $6.2M | +14% |
| Net loss absorbed | $73.3M | $54.9M | $18.4M | +34% |
Questions
How much did Relay Therapeutics's revenue grow quarter over quarter in Q1 2026?
Relay Therapeutics's revenue fell $4.0M (-57%) from $7.0M in Q4 2025 to $3.0M in Q1 2026.